PIK3CA Complete Identifier and Functional Mapping Reference
Section 1: Gene Identifiers
| Database | Identifier | Value |
|---|
| HGNC ID | HGNC:8975 | Approved |
| HGNC Symbol | PIK3CA | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| Ensembl Gene | ENSG00000121879 | Human |
| NCBI Entrez | 5290 | protein-coding |
| OMIM | 171834 | Gene/Locus |
| Gene Group | Phosphatidylinositol 3-kinase family | |
| Aliases | PI3K, PI3K-alpha, p110-alpha, CCM4, CLAPO, CLOVE, CWS5, MCAP, MCM | |
Genomic Location
| Feature | Value |
|---|
| Chromosome | 3 |
| Cytogenetic Band | 3q26.32 |
| Start Position | 179,148,114 |
| End Position | 179,240,093 |
| Strand | + (forward) |
| Genomic Accession | NC_000003.12 |
| Gene Length | 91,979 bp |
Section 2: Transcript Identifiers
Ensembl Transcripts (Total: 15)
| Transcript ID | Biotype | Start | End | UTR5 Start | UTR3 End |
|---|
| ENST00000263967 | protein_coding | 179,148,357 | 179,240,093 | 179,198,750 | 179,240,093 |
| ENST00000462255 | retained_intron | 179,218,209 | 179,235,016 | - | - |
| ENST00000468036 | protein_coding | 179,149,527 | 179,199,179 | 179,198,750 | - |
| ENST00000477735 | protein_coding | 179,148,114 | 179,198,888 | 179,198,750 | - |
| ENST00000643187 | protein_coding | 179,148,574 | 179,235,098 | 179,198,750 | 179,235,098 |
| ENST00000674534 | retained_intron | 179,202,977 | 179,235,084 | - | - |
| ENST00000674622 | nonsense_mediated_decay | 179,210,524 | 179,235,084 | - | 179,235,084 |
| ENST00000675467 | retained_intron | 179,196,019 | 179,235,371 | - | - |
| ENST00000675786 | nonsense_mediated_decay | 179,149,001 | 179,235,084 | 179,198,750 | 179,235,084 |
| ENST00000675796 | retained_intron | 179,226,882 | 179,235,107 | - | - |
| ENST00000876545 | protein_coding | 179,148,589 | 179,235,137 | 179,198,750 | 179,235,137 |
| ENST00000913499 | protein_coding | 179,148,177 | 179,237,493 | 179,198,750 | 179,237,493 |
| ENST00000913500 | protein_coding | 179,148,428 | 179,235,325 | 179,198,750 | 179,235,325 |
| ENST00000955189 | protein_coding | 179,148,186 | 179,235,121 | 179,198,750 | 179,235,121 |
| ENST00000955190 | protein_coding | 179,148,256 | 179,235,120 | 179,198,750 | 179,235,120 |
Summary: 9 protein-coding, 4 retained introns, 2 NMD transcripts
RefSeq Transcripts (Human)
| Accession | Type | Status | MANE Select |
|---|
| NM_006218.4 | mRNA | REVIEWED | Yes (Canonical) |
| XM_006713658 | mRNA | PREDICTED | No |
| XM_054346842 | mRNA | PREDICTED | No |
| XM_054346843 | mRNA | PREDICTED | No |
| XM_054346844 | mRNA | PREDICTED | No |
| XM_054346845 | mRNA | PREDICTED | No |
| XM_054346846 | mRNA | PREDICTED | No |
| XM_054346847 | mRNA | PREDICTED | No |
| XM_054346848 | mRNA | PREDICTED | No |
CCDS
| ID | Description |
|---|
| CCDS43171.1 | Consensus coding sequence |
Canonical Transcript Exons (ENST00000263967) - Total: 21
| Exon ID | Start | End | Length (bp) |
|---|
| ENSE00001493081 | 179,148,357 | 179,148,603 | 247 |
| ENSE00001139995 | 179,198,750 | 179,199,177 | 428 |
| ENSE00000997375 | 179,199,690 | 179,199,899 | 210 |
| ENSE00001077693 | 179,201,290 | 179,201,540 | 251 |
| ENSE00001077692 | 179,203,544 | 179,203,789 | 246 |
| ENSE00001077694 | 179,204,503 | 179,204,588 | 86 |
| ENSE00001077691 | 179,209,595 | 179,209,700 | 106 |
| ENSE00001128470 | 179,210,186 | 179,210,338 | 153 |
| ENSE00001128465 | 179,210,431 | 179,210,565 | 135 |
| ENSE00001077674 | 179,218,210 | 179,218,334 | 125 |
| ENSE00000826291 | 179,219,196 | 179,219,277 | 82 |
| ENSE00000826292 | 179,219,571 | 179,219,735 | 165 |
| ENSE00003485038 | 179,219,949 | 179,220,052 | 104 |
| ENSE00003568097 | 179,220,986 | 179,221,157 | 172 |
| ENSE00003489671 | 179,224,081 | 179,224,187 | 107 |
| ENSE00003485539 | 179,224,700 | 179,224,821 | 122 |
| ENSE00000826297 | 179,225,962 | 179,226,040 | 79 |
| ENSE00000826298 | 179,229,272 | 179,229,442 | 171 |
| ENSE00000826299 | 179,230,004 | 179,230,121 | 118 |
| ENSE00000826300 | 179,230,225 | 179,230,376 | 152 |
| ENSE00001139987 | 179,234,094 | 179,240,093 | 6,000 |
Section 3: Protein Identifiers
UniProt Accessions (Total: 6)
| Accession | Status | Description |
|---|
| P42336 | Reviewed (Swiss-Prot) | Canonical entry |
| A0A2R8Y2F6 | Unreviewed | Isoform |
| A0A6Q8PGN9 | Unreviewed | Isoform |
| A0A6Q8PGV1 | Unreviewed | Isoform |
| C9J951 | Unreviewed | Isoform |
| C9JAM9 | Unreviewed | Isoform |
Canonical Protein (P42336)
| Property | Value |
|---|
| Length | 1,068 amino acids |
| Mass | 124,284 Da |
| Full Name | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform |
| Alternative Names | PI3-kinase p110-alpha, PI3Kalpha, Serine/threonine protein kinase PIK3CA |
RefSeq Proteins (Human)
| Accession | Type | Status |
|---|
| NP_006209.2 | protein | REVIEWED |
| XP_006713721 | predicted_protein | PREDICTED |
| XP_054202817-823 | predicted_protein | PREDICTED |
Protein Domains and Families (InterPro) - Total: 14
| InterPro ID | Name | Type |
|---|
| IPR000341 | PI3K_Ras-bd_dom | Domain |
| IPR000403 | PI3/4_kinase_cat_dom | Domain |
| IPR001263 | PI3K_accessory_dom | Domain |
| IPR002420 | PI3K-type_C2_dom | Domain |
| IPR003113 | PI3K_ABD | Domain |
| IPR037704 | PI3-kinase_alpha_cat | Domain |
| IPR015433 | PI3/4_kinase | Family |
| IPR018936 | PI3/4_kinase_CS | Conserved_site |
| IPR011009 | Kinase-like_dom_sf | Homologous_superfamily |
| IPR016024 | ARM-type_fold | Homologous_superfamily |
| IPR029071 | Ubiquitin-like_domsf | Homologous_superfamily |
| IPR035892 | C2_domain_sf | Homologous_superfamily |
| IPR036940 | PI3/4_kinase_cat_sf | Homologous_superfamily |
| IPR042236 | PI3K_accessory_sf | Homologous_superfamily |
Section 4: Structure Identifiers
Experimental Structures (PDB) - Total: 125+
X-ray Crystallography Structures (Top 50 by resolution)
| PDB ID | Resolution (Å) | Title |
|---|
| 9ASF | 1.77 | HLA-A*03:01 with WT PIK3CA peptide |
| 9CML | 1.75 | p110alpha-RBD with molecular glue D223 |
| 7L1C | 1.96 | HLA-A*03:01 with mutant PIK3CA peptide |
| 8EXL | 1.99 | PI3K-alpha with taselisib |
| 9CWY | 1.98 | HLA-A*03:01 with WT PIK3CA peptide |
| 9CWZ | 2.05 | HLA-A*03:02 with mutant PIK3CA peptide |
| 7RRG | 2.12 | TCR bound to HLA-A*03:01 with PIK3CA peptide |
| 7JIU | 2.12 | PI3Kdelta with compound 2F |
| 6PYS | 2.19 | PI3Kalpha with compound 2-10 |
| 7PG5 | 2.20 | PI3Kalpha crystal structure |
| 9B4U | 2.21 | p110alpha-RBD with breaker compound |
| 4JPS | 2.20 | PI3K alpha with inhibitors |
| 5DXT | 2.25 | p110alpha with GDC-0326 |
| 8SBC | 2.30 | PI3K alpha with brain penetrant inhibitors |
| 6VO7 | 2.31 | PI3K-alpha RBD |
| 4WAF | 2.39 | PI3K alpha with tetrahydropyrazolo compound |
| 7K6M | 2.41 | PI3Kalpha with PF-06843195 |
| 8BFU | 2.41 | Apo p110alpha |
| 7TZ7 | 2.41 | PI3K alpha with inhibitor |
| 8EXO | 2.46 | PI3K-alpha with compound 19 |
| 8EXV | 2.48 | PI3K-alpha with compound 32 |
| 7PG6 | 2.50 | PI3Kalpha with NVP-BYL719 |
| 5UK8 | 2.50 | PI3K-alpha mutant mimic |
| 5FI4 | 2.50 | PI3K with imidazopyridine inhibitor |
| 6GVF | 2.50 | PI3K alpha with benzooxazole compound |
| 8TSA | 2.51 | PI3K p85alpha/p110alpha H1047R with compound 2 |
| 5XGI | 2.56 | PI3K with inhibitor |
| 4L1B | 2.59 | p110alpha with niSH2 of p85alpha |
| 8V8V | 2.61 | PI3Ka H1047R with compound 7 |
| 4ZOP | 2.62 | PI3K alpha with selective inhibitor |
| 8GUD | 2.62 | PI3Kalpha E545K with BYL-719 |
| 4TUU | 2.64 | Isolated p110a subunit |
| 8OW2 | 2.57 | p110alpha with activator 1938 |
| 8TWY | 2.67 | p110 alpha with compound 9 |
| 8EXU | 2.68 | PI3K-alpha with compound 30 |
| 8TSD | 2.70 | PI3K p85alpha/p110alpha with RLY-2608 |
| 8TS7 | 2.71 | PI3K p85alpha/p110alpha |
| 8TS8 | 2.72 | p85alpha/p110alpha H1047R |
| 6GVH | 2.74 | PI3K alpha with benzooxazole compound |
| 7K6N | 2.77 | PI3Kalpha with 11-1575 |
| 9B4T | 2.75 | MRAS-p110alpha complex |
| 3HHM | 2.80 | p110alpha H1047R with wortmannin |
| 4L2Y | 2.80 | p110alpha with compound 9d |
| 5UKJ | 2.80 | PI3K-alpha mutant with sulfonamide |
| 9C15 | 2.81 | KRAS-p110alpha with molecular glue |
| 8AM0 | 2.82 | T1061E PI3Kalpha with GDC-0077/Inavolisib |
| 9E8M | 2.83 | VVD-442 bound to PI3Ka RBD |
| 8TS9 | 2.83 | PI3K H1047R with compound 1 |
| 4TV3 | 2.85 | Isolated p110a with inhibitor |
| 3ZIM | 2.85 | PI3Kalpha with covalent inhibitor |
Cryo-EM Structures
| PDB ID | Resolution (Å) | Title |
|---|
| 8DCP | 2.41 | PI3K alpha with nanobody 3-126 |
| 8GUD | 2.62 | PI3Kalpha E545K with BYL-719 |
| 8GUB | 2.73 | PI3Kalpha H1047R with BYL-719 |
| 8GUA | 2.77 | PI3Kalpha E542K with BYL-719 |
| 7MYN | 2.79 | p110alpha/p85alpha complex |
| 8DCX | 2.80 | PI3K alpha with nanobody 3-159 |
| 7MYO | 2.92 | p110alpha/p85alpha with BYL-719 |
| 9LWS | 2.94 | PI3Kalpha H1047R with UCL-TRO-1938 |
| 8ILR | 3.05 | PI3Kalpha with compound 16 |
| 8ILS | 3.10 | PI3Kalpha with compound 17 |
| 8DD4 | 3.10 | PI3K alpha with nanobody 3-142 |
| 8TU6 | 3.12 | PI3Kalpha cryo-EM |
| 9LWQ | 3.17 | PI3Kalpha with UCL-TRO-1938 |
| 8ILV | 3.19 | PI3Kalpha with compound 18 |
| 9LWR | 3.30 | PI3Kalpha H1047R with UCL-TRO-1938 |
| 8DD8 | 3.40 | PI3K alpha with nanobody, crosslinked |
NMR Structure
| PDB ID | Method | Title |
|---|
| 2ENQ | SOLUTION NMR | C2 domain of PI3-kinase p110 alpha |
Predicted Structure (AlphaFold)
| Model ID | Global pLDDT | Sequence Length | High Confidence (%) |
|---|
| P42336 | 92.50 | 8,722 | 83% |
Section 5: Cross-Species Orthologs
Model Organism Orthologs
| Organism | Gene ID | Symbol | Biotype |
|---|
| Mouse (Mus musculus) | ENSMUSG00000027665 | Pik3ca | protein_coding |
| Rat (Rattus norvegicus) | ENSRNOG00000056371 | Pik3ca | protein_coding |
| Zebrafish (Danio rerio) | ENSDARG00000075456 | pik3ca | protein_coding |
| Fruit fly (Drosophila melanogaster) | FBGN0015278 | Pi3K68D | protein_coding |
| Worm (C. elegans) | WBGENE00009552 | - | - |
| Yeast (S. cerevisiae) | - | - | No ortholog |
Human Paralogs (PI3K Family) - Total: 9
| Gene ID | Symbol | Description |
|---|
| ENSG00000051382 | PIK3CB | PI3K catalytic beta |
| ENSG00000171608 | PIK3CD | PI3K catalytic delta |
| ENSG00000105851 | PIK3CG | PI3K catalytic gamma |
| ENSG00000078142 | PIK3C3 | PI3K class III |
| ENSG00000011405 | PIK3C2A | PI3K class 2 alpha |
| ENSG00000133056 | PIK3C2B | PI3K class 2 beta |
| ENSG00000139144 | PIK3C2G | PI3K class 2 gamma |
| ENSG00000143393 | PI4KB | PI4K beta |
| ENSG00000241973 | PI4KA | PI4K alpha |
Section 6: Clinical Variants & AI Predictions
ClinVar Summary
| Classification | Count |
|---|
| Total Variants | 1,566+ |
| Pathogenic | 52 |
| Likely Pathogenic | 39 |
| Pathogenic/Likely Pathogenic | 10 |
| Uncertain Significance (VUS) | ~300 |
| Likely Benign | ~700 |
| Benign | ~100 |
Top 50 Pathogenic/Likely Pathogenic Variants
| ClinVar ID | HGVS | Protein Change | Classification | Condition |
|---|
| 13652 | c.3140A>G | p.His1047Arg | Pathogenic (Expert) | Multiple overgrowth syndromes |
| 31944 | c.1624G>A | p.Glu542Lys | Pathogenic (Expert) | Cancer/overgrowth syndromes |
| 376476 | c.2176G>A | p.Glu726Lys | Pathogenic (Expert) | MCAP syndrome |
| 39703 | c.2740G>A | p.Gly914Arg | Pathogenic (Expert) | Overgrowth syndromes |
| 13653 | c.3140A>T | p.His1047Leu | Pathogenic | MCAP/cancer |
| 217293 | c.1635G>T | p.Glu545Asp | Pathogenic | Cancer syndromes |
| 13657 | c.1636C>A | p.Gln546Lys | Pathogenic | Cancer syndromes |
| 156446 | c.353G>A | p.Gly118Asp | Pathogenic | MCAP syndrome |
| 376049 | c.263G>A | p.Arg88Gln | Pathogenic | Overgrowth syndromes |
| 376050 | c.1035T>A | p.Asn345Lys | Pathogenic | Cancer syndromes |
| 376247 | c.3145G>A | p.Gly1049Ser | Pathogenic | MCAP syndrome |
| 376470 | c.1357G>A | p.Glu453Lys | Pathogenic | Overgrowth syndromes |
| 376478 | c.241G>A | p.Glu81Lys | Pathogenic | Cancer/overgrowth |
| 376498 | c.1030G>A | p.Val344Met | Pathogenic | Cancer syndromes |
| 217292 | c.3129G>T | p.Met1043Ile | Pathogenic | CLOVES syndrome |
| 31945 | c.1258T>C | p.Cys420Arg | Pathogenic | MCAP syndrome |
| 39704 | c.1133G>A | p.Cys378Tyr | Pathogenic | MCAP syndrome |
| 39705 | c.3139C>T | p.His1047Tyr | Pathogenic | Cancer syndromes |
| 419128 | c.278G>A | p.Arg93Gln | Pathogenic | MCAP syndrome |
| 419222 | c.1093G>A | p.Glu365Lys | Pathogenic | MCAP syndrome |
| 419390 | c.3131A>G | p.Asn1044Ser | Pathogenic | Overgrowth syndromes |
| 521363 | c.1049A>G | p.Asp350Gly | Pathogenic | Cancer syndromes |
| 917489 | c.1132T>C | p.Cys378Arg | Pathogenic | MCAP syndrome |
| 1172582 | c.344G>C | p.Arg115Pro | Pathogenic/LP | MCAP syndrome |
| 1172583 | c.3104C>T | p.Ala1035Val | Pathogenic | Overgrowth syndromes |
| 1057635 | c.2908G>A | p.Glu970Lys | Pathogenic/LP | MCAP syndrome |
| 1098323 | c.2816A>G | p.Asp939Gly | Pathogenic/LP | Cancer syndromes |
| 1198826 | c.277G>A | p.Arg93Trp | Pathogenic/LP | Overgrowth syndromes |
| 1209066 | c.3012G>A | p.Met1004Ile | Pathogenic/LP | Cancer syndromes |
| 13659 | c.1634A>C | p.Glu545Ala | Pathogenic | Cancer syndromes |
| 13656 | c.1634A>G | p.Glu545Gly | Pathogenic | Cancer syndromes |
| 156447 | c.403G>A | p.Glu135Lys | Pathogenic | MCAP syndrome |
| 156448 | c.652G>A | p.Glu218Lys | Pathogenic | Overgrowth syndromes |
| 156449 | c.1066G>A | p.Val356Ile | Pathogenic | Cancer syndromes |
| 376246 | c.3062A>G | p.Tyr1021Cys | Pathogenic | Cancer syndromes |
| 2580765 | c.1034A>G | p.Asn345Ser | Pathogenic | Cancer syndromes |
| 2662642 | c.1798G>A | p.Glu600Lys | Pathogenic | Overgrowth syndromes |
| 45464 | c.1252G>A | p.Glu418Lys | Pathogenic | MCAP syndrome |
| 45466 | c.1637A>G | p.Gln546Arg | Pathogenic | Cancer syndromes |
| 3777340 | c.3193C>T | p.His1065Tyr | Pathogenic | Overgrowth syndromes |
| 3778701 | c.3103G>A | p.Ala1035Thr | Pathogenic | Cancer syndromes |
| 1333708 | c.3127A>C | p.Met1043Leu | Likely pathogenic | Overgrowth |
| 13654 | c.1636C>G | p.Gln546Glu | Likely pathogenic | Cancer |
| 376475 | c.1625A>G | p.Glu542Gly | Likely pathogenic | Cancer |
| 376492 | c.113G>A | p.Arg38His | Likely pathogenic | MCAP syndrome |
| 421698 | c.2758A>G | p.Asn920Asp | Likely pathogenic | Overgrowth |
| 1511013 | c.3145G>T | p.Gly1049Cys | Likely pathogenic | Overgrowth |
| 2505160 | c.2702G>T | p.Cys901Phe | Likely pathogenic | Cancer |
| 995382 | c.325GAA[1] | p.Glu110del | Likely pathogenic (Expert) | MCAP |
| 372875 | c.1259_1261dup | p.Cys420_Pro421insArg | Likely pathogenic | MCAP |
SpliceAI Predictions - Total: 3,028
Top 50 Predicted Splice-Altering Variants (Score ≥ 0.5)
| Variant | Effect | Delta Score |
|---|
| 3:179148600:GAGC:G | donor_gain | 1.00 |
| 3:179148601:AGC:A | donor_gain | 1.00 |
| 3:179148602:GC:G | donor_gain | 1.00 |
| 3:179148602:GCG:G | donor_gain | 1.00 |
| 3:179148604:G:GG | donor_gain | 1.00 |
| 3:179148590:G:GT | donor_gain | 0.99 |
| 3:179148599:CGAGC:C | donor_gain | 0.99 |
| 3:179148600:GAGCG:G | donor_gain | 0.99 |
| 3:179148603:CG:C | donor_loss | 0.99 |
| 3:179148604:G:GC | donor_loss | 0.99 |
| 3:179148605:T:G | donor_loss | 0.99 |
| 3:179148607:A:AT | donor_loss | 0.99 |
| 3:179148608:G:GG | donor_gain | 0.99 |
| 3:179148608:G:C | donor_loss | 0.98 |
| 3:179148607:A:AG | donor_gain | 0.98 |
| 3:179148628:T:TA | donor_gain | 0.96 |
| 3:179148629:A:AA | donor_gain | 0.96 |
| 3:179148630:GCGG:G | donor_gain | 0.95 |
| 3:179148632:G:A | donor_gain | 0.90 |
| 3:179148901:G:GT | donor_gain | 0.86 |
| 3:179148607:AGT:A | donor_gain | 0.85 |
| 3:179148609:T:A | donor_gain | 0.83 |
| 3:179148605:T:TC | donor_gain | 0.81 |
| 3:179148803:C:T | donor_gain | 0.81 |
| 3:179148603:CGTGA:C | donor_gain | 0.80 |
| 3:179148604:GT:G | donor_gain | 0.80 |
| 3:179148605:TGAGT:T | donor_gain | 0.80 |
| 3:179148608:GT:G | donor_gain | 0.80 |
| 3:179148601:AGCGT:A | donor_gain | 0.79 |
| 3:179148602:GCGTG:G | donor_gain | 0.79 |
| 3:179148606:G:GG | donor_gain | 0.78 |
| 3:179148606:GA:G | donor_gain | 0.78 |
| 3:179148124:GGG:G | donor_gain | 0.75 |
| 3:179148125:GGG:G | donor_gain | 0.75 |
| 3:179148610:AG:A | donor_gain | 0.75 |
| 3:179149106:GGTT:G | donor_gain | 0.70 |
| 3:179149132:G:GT | donor_gain | 0.69 |
| 3:179149136:G:GT | donor_gain | 0.68 |
| 3:179149189:T:TA | donor_gain | 0.65 |
| 3:179148636:G:A | donor_gain | 0.65 |
| 3:179148573:T:A | donor_gain | 0.64 |
| 3:179149010:G:T | donor_gain | 0.62 |
| 3:179148625:C:CA | donor_gain | 0.61 |
| 3:179148638:G:GT | donor_gain | 0.58 |
| 3:179149107:GTT:G | donor_gain | 0.55 |
| 3:179149108:TTT:T | donor_gain | 0.55 |
| 3:179149123:AGG:A | donor_gain | 0.53 |
| 3:179149128:TATGG:T | donor_gain | 0.52 |
| 3:179149129:ATGGA:A | donor_gain | 0.52 |
| 3:179149190:T:TA | donor_gain | 0.52 |
AlphaMissense Predictions - Total: 7,111
Top 50 Predicted Pathogenic Missense Variants (Score ≥ 0.9)
| Variant | AA Change | Score | Classification |
|---|
| 3:179198856:T:A | W11R | 0.998 | likely_pathogenic |
| 3:179198856:T:C | W11R | 0.998 | likely_pathogenic |
| 3:179198858:G:C | W11C | 0.995 | likely_pathogenic |
| 3:179198858:G:T | W11C | 0.995 | likely_pathogenic |
| 3:179198872:T:C | M16T | 0.993 | likely_pathogenic |
| 3:179198850:G:A | E9K | 0.988 | likely_pathogenic |
| 3:179198854:T:C | L10P | 0.987 | likely_pathogenic |
| 3:179198859:G:C | G12R | 0.987 | likely_pathogenic |
| 3:179198873:G:A | M16I | 0.987 | likely_pathogenic |
| 3:179198873:G:C | M16I | 0.987 | likely_pathogenic |
| 3:179198873:G:T | M16I | 0.987 | likely_pathogenic |
| 3:179198872:T:A | M16K | 0.984 | likely_pathogenic |
| 3:179198857:G:C | W11S | 0.984 | likely_pathogenic |
| 3:179198872:T:G | M16R | 0.985 | likely_pathogenic |
| 3:179198848:G:A | G8D | 0.977 | likely_pathogenic |
| 3:179198851:A:T | E9V | 0.974 | likely_pathogenic |
| 3:179198854:T:A | L10Q | 0.974 | likely_pathogenic |
| 3:179198848:G:T | G8V | 0.972 | likely_pathogenic |
| 3:179198847:G:T | G8C | 0.962 | likely_pathogenic |
| 3:179198857:G:T | W11L | 0.961 | likely_pathogenic |
| 3:179198851:A:C | E9A | 0.958 | likely_pathogenic |
| 3:179198854:T:G | L10R | 0.953 | likely_pathogenic |
| 3:179198851:A:G | E9G | 0.951 | likely_pathogenic |
| 3:179198856:T:G | W11G | 0.947 | likely_pathogenic |
| 3:179198860:G:T | G12V | 0.945 | likely_pathogenic |
| 3:179198850:G:C | E9Q | 0.942 | likely_pathogenic |
| 3:179198860:G:A | G12D | 0.941 | likely_pathogenic |
| 3:179198845:C:T | S7L | 0.926 | likely_pathogenic |
| 3:179198839:C:A | P5Q | 0.926 | likely_pathogenic |
| 3:179198875:C:A | P17H | 0.922 | likely_pathogenic |
| 3:179198875:C:G | P17R | 0.918 | likely_pathogenic |
| 3:179198839:C:G | P5R | 0.914 | likely_pathogenic |
| 3:179198859:G:T | G12C | 0.912 | likely_pathogenic |
| 3:179198852:A:C | E9D | 0.904 | likely_pathogenic |
| 3:179198852:A:T | E9D | 0.904 | likely_pathogenic |
| 3:179198871:A:G | M16V | 0.892 | likely_pathogenic |
| 3:179198838:C:A | P5T | 0.890 | likely_pathogenic |
| 3:179198839:C:T | P5L | 0.890 | likely_pathogenic |
| 3:179198847:G:A | G8S | 0.882 | likely_pathogenic |
| 3:179198838:C:T | P5S | 0.880 | likely_pathogenic |
| 3:179198848:G:C | G8A | 0.876 | likely_pathogenic |
| 3:179198875:C:T | P17L | 0.873 | likely_pathogenic |
| 3:179198874:C:A | P17T | 0.868 | likely_pathogenic |
| 3:179198844:T:C | S7P | 0.868 | likely_pathogenic |
| 3:179198842:C:T | S6L | 0.858 | likely_pathogenic |
| 3:179198841:T:C | S6P | 0.834 | likely_pathogenic |
| 3:179198874:C:T | P17S | 0.830 | likely_pathogenic |
| 3:179198859:G:A | G12S | 0.806 | likely_pathogenic |
| 3:179198869:T:C | L15S | 0.770 | likely_pathogenic |
| 3:179198865:C:G | H14D | 0.757 | likely_pathogenic |
Section 7: Biological Pathways & Gene Ontology
Pathway Membership (Reactome) - Total: 60
| Pathway ID | Pathway Name | Disease Pathway |
|---|
| R-HSA-109704 | PI3K Cascade | No |
| R-HSA-1257604 | PIP3 activates AKT signaling | No |
| R-HSA-112399 | IRS-mediated signalling | No |
| R-HSA-114604 | GPVI-mediated activation cascade | No |
| R-HSA-1433557 | Signaling by SCF-KIT | No |
| R-HSA-1660499 | Synthesis of PIPs at the plasma membrane | No |
| R-HSA-180292 | GAB1 signalosome | No |
| R-HSA-186763 | Downstream signal transduction | No |
| R-HSA-1963642 | PI3K events in ERBB2 signaling | No |
| R-HSA-198203 | PI3K/AKT activation | No |
| R-HSA-201556 | Signaling by ALK | No |
| R-HSA-202424 | Downstream TCR signaling | No |
| R-HSA-2029485 | Role of phospholipids in phagocytosis | No |
| R-HSA-210993 | Tie2 Signaling | No |
| R-HSA-2424491 | DAP12 signaling | No |
| R-HSA-2730905 | Role of LAT2/NTAL/LAB on calcium mobilization | No |
| R-HSA-373753 | Nephrin family interactions | No |
| R-HSA-389357 | CD28 dependent PI3K/Akt signaling | No |
| R-HSA-416476 | G alpha (q) signalling events | No |
| R-HSA-4420097 | VEGFA-VEGFR2 Pathway | No |
| R-HSA-512988 | IL-3, IL-5 and GM-CSF signaling | No |
| R-HSA-5654689 | PI-3K cascade:FGFR1 | No |
| R-HSA-5654695 | PI-3K cascade:FGFR2 | No |
| R-HSA-5654710 | PI-3K cascade:FGFR3 | No |
| R-HSA-5654720 | PI-3K cascade:FGFR4 | No |
| R-HSA-5673001 | RAF/MAP kinase cascade | No |
| R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | No |
| R-HSA-8851907 | MET activates PI3K/AKT signaling | No |
| R-HSA-8853659 | RET signaling | No |
| R-HSA-9009391 | Extra-nuclear estrogen signaling | No |
| R-HSA-9013149 | RAC1 GTPase cycle | No |
| R-HSA-9013404 | RAC2 GTPase cycle | No |
| R-HSA-9027276 | Erythropoietin activates PI3K | No |
| R-HSA-9028335 | Activated NTRK2 signals through PI3K | No |
| R-HSA-912526 | Interleukin receptor SHC signaling | No |
| R-HSA-912631 | Regulation of signaling by CBL | No |
| R-HSA-9603381 | Activated NTRK3 signals through PI3K | No |
| R-HSA-9607240 | FLT3 Signaling | No |
| R-HSA-9680350 | Signaling by CSF1 (M-CSF) in myeloid cells | No |
| R-HSA-9842663 | Signaling by LTK | No |
| R-HSA-9856530 | PIEZO1/PECAM1/CDH5/KDR signaling in endothelium | No |
| R-HSA-9927354 | Co-stimulation by ICOS | No |
| R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer | Yes |
| R-HSA-1236382 | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | Yes |
| R-HSA-5637810 | Constitutive Signaling by EGFRvIII | Yes |
| R-HSA-1839117 | Signaling by cytosolic FGFR1 fusion mutants | Yes |
| R-HSA-5655253 | Signaling by FGFR2 in disease | Yes |
| R-HSA-5655291 | Signaling by FGFR4 in disease | Yes |
| R-HSA-5655302 | Signaling by FGFR1 in disease | Yes |
| R-HSA-5655332 | Signaling by FGFR3 in disease | Yes |
| R-HSA-9664565 | Signaling by ERBB2 KD Mutants | Yes |
| R-HSA-9665348 | Signaling by ERBB2 ECD mutants | Yes |
| R-HSA-9670439 | Signaling by phosphorylated KIT mutants | Yes |
| R-HSA-9673767 | Signaling by PDGFRA transmembrane/kinase mutants | Yes |
| R-HSA-9673770 | Signaling by PDGFRA extracellular domain mutants | Yes |
| R-HSA-9703465 | Signaling by FLT3 fusion proteins | Yes |
| R-HSA-9703648 | Signaling by FLT3 ITD and TKD mutants | Yes |
| R-HSA-9725370 | Signaling by ALK fusions and point mutants | Yes |
| R-HSA-9842640 | Signaling by LTK in cancer | Yes |
Gene Ontology Annotations - Total: 66
Molecular Function (13 terms)
| GO ID | Term |
|---|
| GO:0016303 | 1-phosphatidylinositol-3-kinase activity |
| GO:0046934 | 1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity |
| GO:0035005 | 1-phosphatidylinositol-4-phosphate 3-kinase activity |
| GO:0004674 | protein serine/threonine kinase activity |
| GO:0106310 | protein serine kinase activity |
| GO:0005524 | ATP binding |
| GO:0030295 | protein kinase activator activity |
| GO:0043560 | insulin receptor substrate binding |
Biological Process (48 terms - TOP 20)
| GO ID | Term |
|---|
| GO:0048015 | phosphatidylinositol-mediated signaling |
| GO:0043491 | phosphatidylinositol 3-kinase/protein kinase B signal transduction |
| GO:0036092 | phosphatidylinositol-3-phosphate biosynthetic process |
| GO:0046854 | phosphatidylinositol phosphate biosynthetic process |
| GO:0007173 | epidermal growth factor receptor signaling pathway |
| GO:0008286 | insulin receptor signaling pathway |
| GO:0048009 | insulin-like growth factor receptor signaling pathway |
| GO:0038084 | vascular endothelial growth factor signaling pathway |
| GO:0050852 | T cell receptor signaling pathway |
| GO:0051897 | positive regulation of PI3K/PKB signal transduction |
| GO:0032008 | positive regulation of TOR signaling |
| GO:0038203 | TORC2 signaling |
| GO:0001525 | angiogenesis |
| GO:0001944 | vasculature development |
| GO:0016477 | cell migration |
| GO:0043542 | endothelial cell migration |
| GO:0030168 | platelet activation |
| GO:0006909 | phagocytosis |
| GO:0032869 | cellular response to insulin stimulus |
| GO:0006006 | glucose metabolic process |
Cellular Component (10 terms)
| GO ID | Term |
|---|
| GO:0005942 | phosphatidylinositol 3-kinase complex |
| GO:0005943 | phosphatidylinositol 3-kinase complex, class IA |
| GO:0005944 | phosphatidylinositol 3-kinase complex, class IB |
| GO:0005737 | cytoplasm |
| GO:0005829 | cytosol |
| GO:0005886 | plasma membrane |
| GO:0030027 | lamellipodium |
| GO:0048471 | perinuclear region of cytoplasm |
| GO:0014704 | intercalated disc |
Section 8: Protein Interactions & Molecular Networks
Protein-Protein Interactions (STRING) - Total: 4,602
Top 50 Highest-Confidence Interactors
| UniProt ID | Gene | Confidence Score |
|---|
| P27986 | PIK3R1 (p85alpha) | 998 |
| P42336 | PIK3CA (self) | 998 |
| O00459 | PIK3R2 (p85beta) | 997 |
| Q92569 | PIK3R3 (p55gamma) | 995 |
| Q8WYR1 | PIK3R5 | 992 |
| P42338 | PIK3CB | 984 |
| O00329 | PIK3CD | 983 |
| P00533 | EGFR | 977 |
| P48736 | PIK3CG | 973 |
| P01116 | KRAS | 952 |
| P35568 | IRS1 | 952 |
| P31749 | AKT1 | 951 |
| P60484 | PTEN | 949 |
| P15056 | BRAF | 931 |
| P04626 | ERBB2 (HER2) | 927 |
| P01111 | NRAS | 921 |
| P04637 | TP53 | 920 |
| Q14155 | BEX4 | 912 |
| O14497 | ARID1A | 911 |
| P22607 | FGFR3 | 902 |
| P35222 | CTNNB1 (beta-catenin) | 890 |
| P16234 | PDGFRA | 867 |
| P21860 | ERBB3 | 856 |
| P12931 | SRC | 847 |
| Q969H0 | FBXW7 | 845 |
| P31751 | AKT2 | 841 |
| Q9Y243 | AKT3 | 839 |
| P03372 | ESR1 | 817 |
| Q15831 | STK11 (LKB1) | 817 |
| Q02750 | MAP2K1 | 815 |
| P51587 | BRCA2 | 812 |
| P10721 | KIT | 810 |
| P28482 | MAPK1 | 810 |
| P01112 | HRAS | 801 |
| Q9UM73 | ALK | 801 |
| P42771 | CDKN2A (p16) | 791 |
| P21359 | NF1 | 790 |
| P40692 | MLH1 | 788 |
| P07949 | RET | 781 |
| P11362 | FGFR1 | 778 |
| P08069 | IGF1R | 776 |
| P30153 | PPP2R1A | 773 |
| P09619 | PDGFRB | 764 |
| Q13485 | SMAD4 | 763 |
| Q6R327 | RAPGEF5 | 757 |
| O60674 | JAK2 | 755 |
| P00519 | ABL1 | 755 |
| P35968 | VEGFR2 (KDR) | 754 |
| O15530 | PDPK1 (PDK1) | 744 |
| P50148 | GNAQ | 741 |
BioGRID Interactions - Total: 303+
Key experimental interactions detected by affinity capture-MS, two-hybrid, and biochemical assays.
IntAct Interactions - Total: 250+
Top 20 High-Confidence Direct Interactions (Score ≥ 0.9)
| Partner | Interaction Type | Score |
|---|
| PIK3R1 | Direct interaction | 0.960 |
| PIK3R1 | Physical association | 0.960 |
| PIK3R2 | Physical association | 0.900 |
| PIK3R3 | Physical association | 0.900 |
| GRB2 | Physical association | 0.800 |
Protein Similarity
Structural/Embedding Similarity (ESM2) - Total: 135
Top 20 Most Similar Proteins
| UniProt ID | Top Similarity | Avg Similarity |
|---|
| A0A0G2K344 | 1.0000 | 0.9872 |
| D3ZGS3 | 0.9998 | 0.9862 |
| P42337 (PIK3CB) | 1.0000 | 0.9872 |
| O88763 | 1.0000 | 0.9875 |
| P32871 | 1.0000 | 0.9869 |
| O35904 | 0.9996 | 0.9874 |
| Q6AZN6 | 0.9996 | 0.9870 |
| P42338 (PIK3CD) | 0.9998 | 0.9867 |
| O00329 (PIK3CG) | 0.9996 | 0.9865 |
| P48736 (PIK3CG) | 0.9997 | 0.9848 |
Sequence Homology (DIAMOND) - Total: 30
| UniProt ID | Top Identity (%) | Bitscore |
|---|
| P42336 (self) | 99.80 | 2182 |
| A0A0G2K344 | 99.70 | 2176 |
| P42337 | 99.70 | 2176 |
| P32871 | 99.80 | 2183 |
| Q5RAY1 | 98.60 | 3256 |
| O00443 | 98.60 | 3260 |
| Q8BTI9 | 98.40 | 2107 |
| Q9Z1L0 | 98.40 | 2109 |
| P42338 | 95.90 | 2079 |
| P48736 | 94.90 | 2119 |
| O02697 | 94.90 | 2118 |
| O00329 | 94.50 | 1987 |
| O35904 | 94.50 | 1983 |
| Q9JHG7 | 94.10 | 2105 |
| Q61194 | 90.10 | 3008 |
| O70173 | 87.40 | 2663 |
| O70167 | 87.40 | 2658 |
| Q0WPX9 | 85.70 | 1576 |
| O75747 | 72.30 | 2189 |
Section 9: Transcription Factor Regulatory Data
PIK3CA is NOT a transcription factor. However, its expression is regulated by several TFs:
Upstream Regulators (TFs that regulate PIK3CA)
| TF Gene | Regulation | Confidence |
|---|
| TP53 | Repression | High |
| YBX1 | Activation | High |
| FOXO3 | Unknown | High |
| SOX9 | Activation | - |
| HIF1A | Unknown | - |
| NFKB | Unknown | Low |
Section 10: Drug & Pharmacology Data
ChEMBL Target Information
| Property | Value |
|---|
| Target ID | CHEMBL4005 |
| Target Type | SINGLE PROTEIN |
| Mechanism | PI3-kinase p110-alpha subunit inhibitor |
| Action Type | INHIBITOR |
| Total Molecules | 7,630 |
| Total Assays | 1,726 |
| Total Activities | 9,474 |
Approved Drugs (Phase 4) - Total: 13
| ChEMBL ID | Drug Name | Type | Indication |
|---|
| CHEMBL2396661 | ALPELISIB (Piqray) | Small molecule | PIK3CA-mutated breast cancer |
| CHEMBL4650215 | INAVOLISIB (Itovebi) | Small molecule | PIK3CA-mutated breast cancer |
| CHEMBL2216870 | IDELALISIB | Small molecule | CLL, FL, SLL |
| CHEMBL3039502 | DUVELISIB | Small molecule | CLL/SLL, FL |
| CHEMBL3218576 | COPANLISIB | Small molecule | FL |
| CHEMBL3545068 | COPANLISIB HCl | Small molecule | FL |
| CHEMBL3643413 | LENIOLISIB | Small molecule | APDS |
| CHEMBL535 | SUNITINIB | Small molecule | RCC, GIST |
| CHEMBL5416410 | DASATINIB | Small molecule | CML, ALL |
| CHEMBL601719 | CRIZOTINIB | Small molecule | ALK+ NSCLC |
| CHEMBL608533 | MIDOSTAURIN | Small molecule | AML |
| CHEMBL1287853 | FEDRATINIB | Small molecule | Myelofibrosis |
| CHEMBL343448 | ROMIDEPSIN | Protein | CTCL |
Phase 3 Clinical Candidates - Total: 7
| ChEMBL ID | Drug Name | Type |
|---|
| CHEMBL1879463 | DACTOLISIB | Small molecule |
| CHEMBL2017974 | BUPARLISIB | Small molecule |
| CHEMBL2387080 | TASELISIB | Small molecule |
| CHEMBL592445 | GEDATOLISIB | Small molecule |
| CHEMBL603469 | LESTAURTINIB | Small molecule |
| CHEMBL165 | RESVERATROL | Small molecule |
| CHEMBL297453 | EPIGALLOCATECHIN GALLATE | Small molecule |
BindingDB Ligands - Total: 12,080+
High-affinity binders with IC50 values in sub-nanomolar to nanomolar range.
PharmGKB Information
| Property | Value |
|---|
| PharmGKB ID | PA33308 |
| VIP Gene | Yes |
| CPIC Guideline | No |
| Chromosome | chr3 |
Section 11: Expression Profiles
Tissue Expression (Bgee)
| Property | Value |
|---|
| Expression Breadth | Ubiquitous |
| Total Present Calls | 284 |
| Max Expression Score | 94.28 |
Top 30 Tissues by Expression Score
| Tissue | Expression Score | Rank |
|---|
| Calcaneal tendon | 94.28 | 2,670 |
| Adrenal tissue | 94.02 | 2,790 |
| Tendon | 92.68 | 3,410 |
| Cortical plate | 89.87 | 4,720 |
| Primordial germ cell (gonad) | 88.34 | 5,440 |
| Male germ line stem cell | 88.24 | 5,480 |
| Tendon of biceps brachii | 88.11 | 5,540 |
| Ventricular zone | 88.04 | 5,580 |
| Secondary oocyte | 87.31 | 5,920 |
| Ganglionic eminence | 87.30 | 5,920 |
| Cartilage tissue | 87.16 | 5,990 |
| Heart right ventricle | 86.41 | 6,330 |
| Skin of hip | 86.30 | 6,390 |
| Bone marrow | 86.17 | 6,450 |
| Biceps brachii | 86.16 | 6,450 |
| Colonic epithelium | 86.15 | 6,460 |
| Endometrial stromal cell | 85.94 | 6,550 |
| Popliteal artery | 85.78 | 6,630 |
| Tibial artery | 85.77 | 6,630 |
| Subcutaneous adipose tissue | 85.75 | 6,640 |
| Abdominal adipose tissue | 85.71 | 6,660 |
| Connective tissue | 85.68 | 6,680 |
| Adipose tissue | 85.67 | 6,680 |
| Bone marrow cell | 85.64 | 6,690 |
| Omental fat pad | 85.58 | 6,720 |
| Peritoneum | 85.52 | 6,750 |
| Artery | 85.48 | 6,770 |
| Biceps brachii skeletal muscle | 85.47 | 6,780 |
| Postcentral gyrus | 85.40 | 6,810 |
| Medial globus pallidus | 85.18 | 6,910 |
Cell Type Expression (Top 30)
| Cell Type | Expression Score |
|---|
| Primordial germ cell | 88.34 |
| Male germ line stem cell | 88.24 |
| Secondary oocyte | 87.31 |
| Endometrial stromal cell | 85.94 |
| Bone marrow cell | 85.64 |
| Endothelial cell | 84.48 |
| Monocyte | 83.90 |
| Leukocyte | 83.82 |
| Mononuclear cell | 83.74 |
| Buccal mucosa cell | 82.45 |
| Oocyte | 79.90 |
| Granulocyte | 79.89 |
Section 12: Disease Associations
Mendelian/Monogenic Diseases (GenCC) - Total: 7
| Disease | OMIM/MONDO | Classification | Inheritance | Evidence |
|---|
| Megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP) | OMIM:602501 | Strong | AD | Multiple submitters |
| Cowden syndrome 5 | OMIM:615108 | Limited | AD | Labcorp |
| Cowden disease | ORPHA:201 | Supportive | AD | Orphanet |
| Vascular malformation | MONDO:0024291 | Strong | AD | PanelApp |
| Familial ovarian cancer | MONDO:0016248 | No known relationship | Unknown | ClinGen |
Orphanet Disease Associations - Total: 15
| Orphanet ID | Disease Name | Type | Gene Count |
|---|
| 60040 | MCAP syndrome | Malformation syndrome | 1 |
| 140944 | CLOVES syndrome | Malformation syndrome | 1 |
| 168984 | CLAPO syndrome | Malformation syndrome | 1 |
| 201 | Cowden syndrome | Clinical subtype | 9 |
| 276280 | Hemihyperplasia-multiple lipomatosis syndrome | Malformation syndrome | 1 |
| 314662 | Segmental progressive overgrowth with FAH | Disease | 1 |
| 99802 | Hemimegalencephaly | Malformation syndrome | 3 |
| 714737 | Diffuse capillary malformation with overgrowth | Morphological anomaly | 2 |
| 90308 | Capillary-lymphatic-venous malformation | Disease | 2 |
| 295239 | Macrodactyly of fingers, unilateral | Clinical subtype | 1 |
| 295243 | Macrodactyly of toes, unilateral | Clinical subtype | 1 |
| 2495 | Meningioma | Disease | 12 |
| 210159 | Adult hepatocellular carcinoma | Disease | 9 |
| 144 | Lynch syndrome | Disease | 9 |
| 221061 | Familial cerebral cavernous malformation | Malformation syndrome | 4 |
HPO Phenotype Associations - Total: 383
Top 50 Phenotype Terms
| HPO ID | Phenotype |
|---|
| HP:0000006 | Autosomal dominant inheritance |
| HP:0000256 | Macrocephaly |
| HP:0001249 | Intellectual disability |
| HP:0001250 | Seizure |
| HP:0001263 | Global developmental delay |
| HP:0001252 | Hypotonia |
| HP:0000238 | Hydrocephalus |
| HP:0000717 | Autism |
| HP:0001028 | Hemangioma |
| HP:0001052 | Nevus flammeus |
| HP:0001004 | Lymphedema |
| HP:0000324 | Facial asymmetry |
| HP:0000965 | Cutis marmorata |
| HP:0000505 | Visual impairment |
| HP:0000316 | Hypertelorism |
| HP:0000158 | Macroglossia |
| HP:0001156 | Brachydactyly |
| HP:0001159 | Syndactyly |
| HP:0001161 | Hand polydactyly |
| HP:0000365 | Hearing impairment |
| HP:0000518 | Cataract |
| HP:0000508 | Ptosis |
| HP:0000098 | Tall stature |
| HP:0000767 | Pectus excavatum |
| HP:0000969 | Edema |
| HP:0001012 | Multiple lipomas |
| HP:0001031 | Subcutaneous lipoma |
| HP:0000771 | Gynecomastia |
| HP:0001048 | Cavernous hemangioma |
| HP:0001054 | Numerous nevi |
| HP:0001067 | Neurofibroma |
| HP:0000347 | Micrognathia |
| HP:0000337 | Broad forehead |
| HP:0000348 | High forehead |
| HP:0000293 | Full cheeks |
| HP:0000218 | High palate |
| HP:0000154 | Wide mouth |
| HP:0000107 | Renal cyst |
| HP:0000138 | Ovarian cyst |
| HP:0000820 | Thyroid abnormality |
| HP:0000853 | Goiter |
| HP:0000854 | Thyroid adenoma |
| HP:0000716 | Depression |
| HP:0000739 | Anxiety |
| HP:0000712 | Emotional lability |
| HP:0000737 | Irritability |
| HP:0001251 | Ataxia |
| HP:0001260 | Dysarthria |
| HP:0001269 | Hemiparesis |
| HP:0001276 | Hypertonia |
GWAS Associations - Total: 8
| Study ID | Trait | P-value |
|---|
| GCST90002392 | Mean corpuscular volume | 4.0e-23 |
| GCST90002390 | Mean corpuscular hemoglobin | 2.0e-19 |
| GCST90002403 | Red blood cell count | 2.0e-16 |
| GCST90002397 | Mean spheric corpuscular volume | 1.0e-11 |
| GCST90002396 | Mean reticulocyte volume | 1.0e-10 |
| GCST90002406 | Reticulocyte fraction of red cells | 5.0e-09 |
| GCST010002 | Refractive error | 2.0e-09 |
| GCST005993 | Mean corpuscular hemoglobin | 3.0e-08 |
Summary Statistics
| Category | Count |
|---|
| Gene identifiers | 5 databases |
| Transcripts (Ensembl) | 15 |
| RefSeq transcripts (human) | 9+ |
| Exons (canonical) | 21 |
| UniProt entries | 6 |
| InterPro domains | 14 |
| PDB structures | 125+ |
| Model organism orthologs | 5 |
| Human paralogs | 9 |
| ClinVar variants | 1,566+ |
| Pathogenic variants | 52 |
| SpliceAI predictions | 3,028 |
| AlphaMissense predictions | 7,111 |
| Reactome pathways | 60 |
| GO annotations | 66 |
| STRING interactions | 4,602 |
| IntAct interactions | 250+ |
| ChEMBL molecules | 7,630 |
| Approved drugs | 13 |
| Orphanet diseases | 15 |
| HPO phenotypes | 383 |
| GWAS associations | 8 |
Reference compiled from: HGNC, Ensembl, NCBI, UniProt, PDB, AlphaFold, ClinVar, SpliceAI, AlphaMissense, Reactome, Gene Ontology, STRING, IntAct, BioGRID, ChEMBL, BindingDB, PharmGKB, Bgee, GenCC,
Orphanet, HPO, GWAS Catalog
I’ve compiled a comprehensive cross-database identifier and functional mapping reference for human PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha).
Key highlights:
- PIK3CA is one of the most frequently mutated oncogenes in human cancer
- The canonical hotspot mutations (H1047R, E542K, E545K) are among the most common cancer-driving mutations
- 125+ experimental structures in PDB, making it one of the most structurally characterized kinases
- 13 FDA-approved drugs target this protein, including the PI3Kα-selective inhibitors alpelisib (Piqray) and inavolisib (Itovebi) for PIK3CA-mutated breast cancer
- Ubiquitous tissue expression with highest levels in tendon, adrenal tissue, and developing brain
- Associated with overgrowth syndromes (MCAP, CLOVES, CLAPO) and Cowden syndrome
- 7,111 AlphaMissense predictions and 3,028 SpliceAI predictions available for variant interpretation